Market research
INDSWFTLAB.NSE Ind-Swift Laboratories Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 30B
- P/E ratio
- 50.38
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.79
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE915B01019
- Market cap
- 30B
- P/E ratio
- 50.38
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.79
About
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Research context
Ind-Swift Laboratories Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the INDSWFTLAB.NSE discussion.
5 years, 6 months ago
Ind-Swift Laboratories Limited is currently in a long term uptrend where the price is trading 30.9% above its 200 day moving average.
From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.
Ind-Swift Laboratories Limited's total revenue rose by 11.1% to $2B since the same quarter in the previous year.
Its net income has increased by 228.0% to $115M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.0% to $549M since the same quarter in the previous year.
Based on the above factors, Ind-Swift Laboratories Limited gets an overall score of 4/5.